Immatics N.V SEC Filings

Immatics N.V., a clinical-stage biotech focused on PRAME-targeted cancer therapies, is conducting a public offering of its ordinary shares listed on Nasdaq as “IMTX.” The company intends to use the net proceeds to fund continued research and development across its PRAME pipeline, support manufacturing and potential commercialization of product candidates, and for working capital and general corporate purposes.

Immatics highlights updated Phase 1a data for its second-generation PRAME cell therapy IMA203CD8, showing a cORR of 36% (23/64), ORR of 46% (32/69) and median duration of response of 9.2 months at a 14‑month median follow-up. In a small ovarian carcinoma subgroup (N=5) at higher dose levels, two patients had confirmed partial responses and one had an unconfirmed partial response. As of September 30, 2025, cash and cash equivalents were €334.9 million and total shareholders’ equity was €416.7 million, providing a substantial capital base ahead of this raise.

Immatics N.V. (IMTX) submitted a Form 6-K to provide investors with an interim report for the three- and nine-month period ended September 30, 2025 and a related press release with its third quarter 2025 financial results and business update. The interim report is furnished as Exhibit 99.1 and the press release as Exhibit 99.2.

The interim report and Exhibit 99.1 are also incorporated by reference into Immatics' existing Form S-8 and Form F-3 registration statements, meaning those registration statements now include the updated information from this interim report.

Immatics N.V. (IMTX) reported updated early‑stage clinical results for its bispecific TCR candidates and outlined next steps. In Phase 1a, IMA402 (PRAME) treated 80 heavily pre‑treated patients across doses from 0.02–30 mg. A provisional RP2D range of 10–30 mg was identified; the MTD was not reached, and tolerability was favorable with low‑grade CRS (Grade 1 33%, Grade 2 5%, Grade 4 1%), no ICANS and no drug‑related Grade 5 events.

Within the RP2D range, 20 efficacy‑evaluable patients showed a confirmed objective response rate of 30% (6/20), including 29% (4/14) in melanoma. Tumor shrinkage occurred in 55% (11/20) and disease control in 65% (13/20). All six confirmed responses were ongoing at cutoff, with two complete metabolic responses (ongoing at 8 and 18 months).

IMA401 (MAGEA4/8) enrolled 55 patients across 0.0066–2.5 mg, establishing a provisional RP2D of 1–2 mg with low‑grade CRS (24% G1, 11% G2), no ≥Grade 3 CRS and no ICANS; three dose‑limiting events occurred at 2.5 mg. A longest confirmed response exceeded two years. The company is advancing IMA402 to Phase 1b (monotherapy and checkpoint inhibitor combinations) and exploring IMA401+IMA402 combinations in sqNSCLC; it also deprioritized IMA204 and ACTallo.

Immatics N.V. appointed Amie Krause as chief people officer, effective October 27, 2025. Krause brings more than 20 years of experience aligning talent and strategy at global biopharmaceutical companies. She previously held senior HR leadership roles at Dompé, Revance Therapeutics, Atara Biotherapeutics, and spent over a decade at Amgen across multiple regions.

The company issued a press release attached as Exhibit 99.1. This report (excluding Exhibit 99.1) is incorporated by reference into Immatics’ Form S-8 and Form F-3 registration statements.

Baker Bros. Advisors and affiliated persons report beneficial ownership of 10,168,901 ordinary shares of Immatics N.V., representing 8.4% of the company’s outstanding common stock based on 121,550,169 shares outstanding as reported in the issuer's public filing. The reported holdings are held by two funds (Life Sciences and 667) for which the adviser has sole voting and dispositive power, with 9,354,564 shares held by Life Sciences and 814,337 shares held by 667. This filing amends prior Schedule 13G disclosures and clarifies ownership and control relationships among the adviser, its GP and two individual reporting persons.